Hypertension, or high blood pressure, remains a leading cause of cardiovascular disease globally. Recent advancements in its management have shifted toward personalized approaches, recognizing the role of genetics, lifestyle, and emerging therapies. Developing new antihypertensive drugs and adopting digital health technologies pave the way for improved management and patient outcomes.

One of the most significant advancements in hypertension therapy is the development of angiotensin receptor-neprilysin inhibitors (ARNIs). These drugs, which combine the effects of angiotensin receptor blockers (ARBs) with neprilysin inhibitors, have effectively reduced blood pressure and improved heart failure outcomes. Sacubitril/valsartan, a prominent ARNI, has become a key treatment option, particularly for patients with heart failure and reduced ejection fraction (HFrEF).

In addition, precision medicine approaches are increasingly being adopted in hypertension management. Genetic testing can help identify patients who may respond better to specific drug classes, such as calcium channel blockers or beta-blockers. This personalized approach reduces trial-and-error in medication selection, leading to more effective blood pressure control.

Remote monitoring tools, including wearable blood pressure monitors and smartphone apps, have revolutionized hypertension management. These tools allow continuous blood pressure monitoring, enabling timely interventions and medication adjustments. Integrating these technologies with telemedicine platforms offers additional convenience, particularly for patients with limited access to in-person care.